Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
171.4 BRL | -2.16% | -.--% | -16.49% |
09:44am | Biogen, Eisai Say Alzheimer's Maintenance Treatment Application Accepted by US FDA | MT |
06-06 | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's enterprise value to sales, at 3.76 times its current sales, is high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.49% | 32.82B | - | ||
+0.82% | 91.94B | A- | ||
-1.32% | 38.74B | A- | ||
+64.45% | 26.66B | A | ||
-16.31% | 15.32B | C | ||
-11.38% | 11.65B | D+ | ||
+173.10% | 10.37B | D | ||
-49.84% | 10.12B | B | ||
+4.64% | 9.06B | B+ | ||
-16.26% | 7.46B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BIIB Stock
- BIIB34 Stock
- Ratings Biogen Inc.